Special Issue "Antibiotics"
A special issue of Pharmaceuticals (ISSN 1424-8247).
Deadline for manuscript submissions: closed (31 March 2010)
Dr. Mark C. Bagley
School of Chemistry, Main Building, Cardiff University, Park Place, Cardiff, CF10 3AT, Wales, UK
Interests: Heterocyclic chemistry, synthetic chemistry and ageing research, synthetic chemistry and tissue engineering, synthetic chemistry and cell signalling, synthetic chemistry and chemical engineering, Microwave- assisted synthesis and methodology
Dr. John Spencer
University of Greenwich at Medway, Chatham ME4 4TB, UK
Antibiotics are central to healthcare, society and medicinal chemistry and the field is constantly evolving, in tandem with the bacteria that they aim to eradicate. The constant challenges facing us still pertain to the effectiveness of these agents in disease treatment and management to lessen the heavy burden on society. As a leading scientist in this area, we invite you to contribute an article, review or communication to this special edition on “Antibiotics” with specific relevance to the antibiotics field. Specific topics include, but are not limited to: prevention, new therapeutic agents, drug discovery, diagnostics and drug resistance.
Dr. Mark C. Bagley
Dr. John Spencer
All manuscripts should be submitted to firstname.lastname@example.org with a copy to the Guest Editor. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed Open Access monthly journal published by MDPI.
- antibacterial activity
- bacterial metabolism and biosynthesis
- bacterial resistance
- clinical trials
- combinatorial libraries
- drug discovery
- medicinal chemistry
- mode of action
- natural products
- quorum sensing
Pharmaceuticals 2010, 3(3), 679-701; doi:10.3390/ph3030679
Received: 18 December 2009; in revised form: 8 March 2010 / Accepted: 10 March 2010 / Published: 15 March 2010| Download PDF Full-text (484 KB) | Download XML Full-text
Article: Lessons Learned from Surveillance of Antimicrobial Susceptibilities of Pseudomonas aeruginosa at a Large Academic Medical Center
Pharmaceuticals 2010, 3(4), 1070-1083; doi:10.3390/ph3041070
Received: 17 December 2009; in revised form: 22 March 2010 / Accepted: 1 April 2010 / Published: 1 April 2010| Download PDF Full-text (153 KB)
Pharmaceuticals 2010, 3(4), 1139-1161; doi:10.3390/ph3041139
Received: 24 March 2010; in revised form: 8 April 2010 / Accepted: 14 April 2010 / Published: 19 April 2010| Download PDF Full-text (439 KB)
Review: Health Economics of Antibiotics
Pharmaceuticals 2010, 3(5), 1348-1359; doi:10.3390/ph3051348
Received: 29 March 2010; in revised form: 19 April 2010 / Accepted: 23 April 2010 / Published: 29 April 2010| Download PDF Full-text (200 KB) | Download XML Full-text
Review: Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections
Pharmaceuticals 2010, 3(5), 1374-1393; doi:10.3390/ph3051374
Received: 26 March 2010; in revised form: 20 April 2010 / Accepted: 30 April 2010 / Published: 11 May 2010| Download PDF Full-text (210 KB) | Download XML Full-text
Review: Beneficial and Harmful Interactions of Antibiotics with Microbial Pathogens and the Host Innate Immune System
Pharmaceuticals 2010, 3(5), 1694-1710; doi:10.3390/ph3051694
Received: 31 March 2010; in revised form: 26 April 2010 / Accepted: 24 May 2010 / Published: 25 May 2010| Download PDF Full-text (101 KB) | Download XML Full-text
Pharmaceuticals 2010, 3(7), 1988-2006; doi:10.3390/ph3071988
Received: 29 April 2010; in revised form: 3 June 2010 / Accepted: 23 June 2010 / Published: 24 June 2010| Download PDF Full-text (194 KB)
Review: Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery
Pharmaceuticals 2010, 3(7), 2268-2290; doi:10.3390/ph3072268
Received: 15 June 2010 / Accepted: 19 July 2010 / Published: 20 July 2010| Download PDF Full-text (180 KB)
Pharmaceuticals 2010, 3(8), 2380-2386; doi:10.3390/ph3082380
Received: 13 May 2010; in revised form: 8 July 2010 / Accepted: 13 July 2010 / Published: 26 July 2010| Download PDF Full-text (98 KB)
Review: Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review
Pharmaceuticals 2010, 3(8), 2568-2591; doi:10.3390/ph3082568
Received: 2 July 2010; in revised form: 22 July 2010 / Accepted: 3 August 2010 / Published: 12 August 2010| Download PDF Full-text (205 KB)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Manuscript ID: Pharmaceuticals-antibiotics-20091110-Di Stefano-it
Type of Paper: Review
Title: Rational Use of Antibiotics in the Treatment of Functional Bowel Disorders
Authors: M. Di Stefano, C. Mengoli and G.R. Corazza
Affiliation: Department of Medicine, University of Pavia, Foundation IRCCS “S.Matteo” Hospital, Piazzale Camillo Golgi 19, Pavia 27100, Italy; E-Mail: email@example.com
Abstract: Functional gastrointestinal symptoms such us bloating, fullness, flatulence, diarrhea, and constipation due to irritable bowel syndrome (IBS) were recently erroneously attributed to small bowel bacterial overgrowth, a condition depending on the presence of an increased number of bacteria in the small bowel. This association provoked an incorrect use of antibiotics. However, antibiotics could be effective in the treatment of functional complaints, but only in a subgroup of patients, characterized by an increase of fermentation at colonic level. In this review, we have commented on the rationale for antibiotic use in IBS and revised the papers suggesting the incorrect pathophysiological link between IBS and small bowel bacterial overgrowth.
Last update: 20 July 2010